Instances of patients receiving UGT included those enrolled on phase I trials of agents not requiring biomarkers, or treatments based on previous clinical trial data, for example, pazopanib for sarcoma and venetoclax for leukemia. The gene discussed is SLC35A2; the disease is sarcoma.